NCT03194152 is a NA clinical trial of Peanut in T2D, sponsored by Harvard School of Public Health (HSPH).

Who is sponsoring NCT03194152?

NCT03194152 is sponsored by Harvard School of Public Health (HSPH).

What drugs are being tested in NCT03194152?

Interventions in NCT03194152: Peanut, Control.

Is NCT03194152 still recruiting?

NCT03194152 is currently completed. Last updated 28 February 2019.

Last reviewed 2019-02-28 · How we verify

NCT03194152

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population

Completed NA Last updated 28 February 2019

What this trial tests

NA trial testing Peanut in T2D in 238 participants. Completed in 1 March 2018.

Timeline

24 October 2017

Primary endpoint
1 March 2018

1 March 2018

Quick facts

Lead sponsor	Harvard School of Public Health (HSPH)
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	238
Start date	24 October 2017
Primary completion	1 March 2018
Estimated completion	1 March 2018
Sites	1 location across China

Drugs / interventions tested

Peanut — full drug profile →
Control

Conditions studied

T2D — all drugs for T2D →

Sponsor

Harvard School of Public Health (HSPH)

Who can join

Adults 20 to 65, any sex, with T2D. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 2 parallel-arm randomized controlled study with free-living subjects on self-selected diets. The objective of this study is to compare the effects of two servings of peanuts with an isocaloric matched refined carbohydrate snack food on glucose, lipids and lipoproteins and cardiovascular health risk factors, satiety and gut microbiota in 250 Chinese participants at risk for metabolic syndrome (overweight/obese, enlarged waist circumference, elevated LDL-cholesterol, prehypertension, and/or prediabetes). The investigators hypothesize that the inclusion of 2 serving of peanuts in the diet will decrease blood glucose, LDL-cholesterol, and improve satiety sanctification between meals and gut microbiota compared to the control group and baseline.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Modulating the Microbiota as a Therapeutic Intervention for Type 2 Diabetes.
Huda MN, Kim M, Bennett BJ. · · 2021 · cited 89× · PMID 33897618 · DOI 10.3389/fendo.2021.632335
Replacing white rice bars with peanuts as snacks in the habitual diet improves metabolic syndrome risk among Chinese adults: a randomized controlled trial.
Wang D, Sun L, Liu X, Niu Z, et al · · 2021 · cited 9× · PMID 33236043 · DOI 10.1093/ajcn/nqaa307

Verify or expand the search:

Other trials of Peanut

Trials testing the same drug.

NCT03654651 — Peanuts and Glycemic Control · Phase 2 · completed

Other recruiting trials for T2D

Currently open trials in the same condition.

NCT07005362 — Fitbit and AI Chatbot in Sedentary Primary Care Patients With T2D · recruiting
NCT06445335 — Prevalence of NAFLD in T2DM Patients · NA · active not recruiting

Other Harvard School of Public Health (HSPH) trials

Trials by the same sponsor.

NCT07493772 — Multiple Micronutrient Supplementation With Digital Layering Among Adolescents in Tanzania · NA · not yet recruiting
NCT06982339 — Beat the Heat Boston · NA · recruiting
NCT06765863 — LIFT-UP: Randomized Controlled Trial of Fortification of Human Milk · NA · recruiting
NCT06102044 — Zinc Supplementation for Young Infants With Clinical Severe Infection in Tanzania · Phase 3 · recruiting
NCT06390943 — Low Birthweight and Preterm Infant Feeding Trial and Supportive Care Package: Implementation Research · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03194152 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Harvard School of Public Health (HSPH)
Last refreshed: 28 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03194152.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing